Philip Denner is an experienced translational research and technology leader with over 20 years in academia and industry, focused on advancing core research infrastructure, laboratory automation, and high-content screening for biomedical discovery. He currently serves at the German Center for Neurodegenerative Diseases (DZNE) as Head of the Laboratory Automation Technologies core facility, where he leads multidisciplinary teams, develops strategic partnerships, and drives technology-focused innovation. Trained in biochemistry and neurochemistry and preclinical drug development, Dr. Denner has built and scaled platforms spanning image-based phenotypic screening, advanced human CNS cell models, and translational assay pipelines. His work has contributed to high-impact publications, patents, and major collaborative initiatives, including Helmholtz-funded technology Head of Core Research Facilities & Services DZNE (interim), Head of CRFS Laboratory Automation Technologies German Center for Neurodegenerative Diseases (DZNE) Country: Germany City: Bonn State:
programs. He is recognized for connecting discovery science with operational excellence to deliver robust, scalable tools for neuroscience and broader lifescience research.
Associated Grants
-
Development and Validation of Labeled Antibodies Against Mitochondrial and Oxidative Stress-Related Targets for Parkinson’s Disease Research
2026